Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (LLY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Eli Lilly and Company Raises FY 2012 EPS Guidance; Reaffirms FY 2012 Revenue Guidance
Eli Lilly and Company raised its fiscal 2012 earnings per share (EPS) guidance and now expects fiscal 2012 earnings per share to be in the range of $3.14 to $3.29 on a reported basis and $3.15 to $3.30 on a non-GAAP basis. The Company also announced that it anticipates fiscal 2012 revenue of between $21.8 billion and $22.8 billion. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $3.18 and revenues of $22.4 billion for fiscal 2012.
Latest Developments for Eli Lilly and Co
- Eli Lilly And Co Lymphoma Drug Fails In Late-Stage Trial-Reuters
- Eli Lilly And Co And Boehringer Ingelheim Pharmaceuticals, Inc. Announces Retrospective Analysis Of Linagliptin Data In Sub-Populations With Type 2 Diabetes
- Eli Lilly And Co CFO Rice To Become Interim CEO-Reuters
- Eli Lilly And Co Reaffirms FY 2013 Guidance
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters